BioSpace News Archive

Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, and Evotec SE (FSE: EVT; NASDAQ: EVO), a global pharmaceutical and life science company, and leading developer of iPSC cell technologies for therapeutic applications, are pleased to announce an exclusive global strategic partnership to develop a best-in-class cell therapy treatment for people living with insulin-dependent diabetes

VBL Therapeutics announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.

Kamada Ltd. announced financial results for the three months ended March 31, 2022.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto , President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced the presentation of preclinical pharmacokinetics (PK) and biodistribution data for its lead development candidate, NT-0231.

Vyriad, Inc. announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, Inc. with participation from existing investors.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2022.

Forensics laboratories performing human identification in criminal casework and database cases have a new option for a capillary electrophoresis (CE) instrument to support their workflow.

Galmed updates business and clinical development strategy to better leverage Aramchol’s anti-fibrotic effects.

Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., welcomes the recently announced public formulary coverage for AJOVY® (fremanezumab) by Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland.